Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001740
Filing Date
2025-08-13
Accepted
2025-08-13 16:05:37
Documents
71
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q hypd-20250630x10q.htm   iXBRL 10-Q 1989553
2 EX-10.8 hypd-20250630xex10d8.htm EX-10.8 22253
3 EX-31.1 hypd-20250630xex31d1.htm EX-31.1 15295
4 EX-32.1 hypd-20250630xex32d1.htm EX-32.1 5779
5 EX-32.2 hypd-20250630xex32d2.htm EX-32.2 6017
  Complete submission text file 0001410578-25-001740.txt   8868859

Data Files

Seq Description Document Type Size
6 EX-101.SCH hypd-20250630.xsd EX-101.SCH 73250
7 EX-101.CAL hypd-20250630_cal.xml EX-101.CAL 50612
8 EX-101.DEF hypd-20250630_def.xml EX-101.DEF 194452
9 EX-101.LAB hypd-20250630_lab.xml EX-101.LAB 441704
10 EX-101.PRE hypd-20250630_pre.xml EX-101.PRE 353953
74 EXTRACTED XBRL INSTANCE DOCUMENT hypd-20250630x10q_htm.xml XML 1904009
Mailing Address 23461 SOUTH POINTE DRIVE, SUITE 390 LAGUNA HILLS CA 92653
Business Address 23461 SOUTH POINTE DRIVE, SUITE 390 LAGUNA HILLS CA 92653 833-393-6684
HYPERION DEFI, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38365 | Film No.: 251211504
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)